Yokota, Kenji

Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma

Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 2,246

Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study

Kobayashi, T., Iwama, S., Yasuda, Y., Okada, N., Tsunekawa, T., Onoue, T., Takagi, H., Hagiwara, D., Ito, Y., Morishita, Y., et al. (2018) · Journal of the Endocrine Society

Cancer Immunotherapy and BiomarkersThyroid Disorders and Treatments

Cited by 203

Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study

Okada, N., Iwama, S., Okuji, T., Kobayashi, T., Yasuda, Y., Wada, E., Onoue, T., Goto, M., Sugiyama, M., Tsunekawa, T., et al. (2020) · British Journal of Cancer

Cancer Immunotherapy and BiomarkersThyroid Disorders and Treatments

Cited by 78